Clinical Trials in Egypt / NCT07078916
Starting soon
Not applicable
MOTOR TRAINING VERSUS MOTOR COGNITIVE TRAINING IN ATHLETES WITH CHRONIC ANKLE INSTABILITY
NCT07078916 · tracked via the Priya Life Science Egypt tracker
Condition(s) studied
Chronic Ankle Instability, CAI
Investigational drug(s) / intervention(s)
Motor-Cognitive Training Group (OLBA + BlazePod™)Motor Training Group (OLBA Only)
Motor-Cognitive Training Group (OLBA + BlazePod™): Arm 1 participant will receive the One-leg-balance activity using visual feedback BlazePod technology as a dual motor-cognitive task training.
Motor Training Group (OLBA Only): Arm 2 participant will receive a the One-leg-balance activity as a single motor task.
Study summary
This study aims to evaluate the effect of one-leg balance activity (OLBA) combined with visual feedback using BlazePod™ as a dual motor-cognitive rehabilitation task in basketball players with Chronic Ankle Instability (CAI). The intervention will be compared to OLBA alone as a motor task. Outcomes measured include dynamic balance, sense of instability, response time, athletic performance, and self-reported physical function. This study will help improve rehabilitation strategies for athletes suffering from ankle instability.
Eligibility
Inclusion Criteria:
* Young adult basketball athletes aged between (18 - 30) years.
* A history of unilateral one or more significant ankle inversion injury occurred at least 1 year before participation in the study.
* Interruption of physical activity or cessation from training for at least 24 hours following injury.
* Report episodes of giving way and sense of instability of the affected ankle.
* Two episodes of giving way or/ recurrent inversion injury should be reported by the patient before study enrollment at least two times in the last 6 months.
* Cumberland Ankle Instability Tool (CAIT) patient scores \< 24.
Exclusion Criteria:
* A history of previous surgery or fracture to musculoskeletal structure (bone, joint, etc.) in the limb of the affected ankle.
* Acute lower limb sprain in the last 3 months before enrollment in the study resulting in interruption of physical activity for 1 day.
* Any disorder or disease that could affect the balance as vestibular disorders, eye injury, and so on.
* Any athlete who participates in any formal or informal rehabilitation.
* Participants who will not commit to two successive sessions will also be considered for exclusion.
* If they received NSAID 2 weeks before enrollment in the study.
Primary outcome measure(s)
- Dynamic balance — At baseline and after 4 weeks of intervention
Dynamic balance will be assessed using the Y-Balance Test, a reliable and valid tool for measuring postural control in three directions: anterior, posteromedial, and posterolateral. The participant will be asked to stand on the injured leg, then using another leg to reach the maximal point along the line in the three different directions, the directions named concerning the contact leg. The length of the line is normalized by the length of the patient's limb which is measured from ASIS to the medial malleolus. The goal of this test is to reach maximum excursion in every direction without shifting weight to or coming to rest on this foot of the reaching limb and then return the reaching limb to the beginning position in the center. Three trials in each direction to be familiarized. Actual trials will be 3 trials and best score will be calculated, The test will be conducted at baseline and after 4 weeks of intervention. - Sense of instability — The CAIT will be administered at baseline and after 4 weeks of intervention.
Sense of ankle instability will be assessed using the Cumberland Ankle Instability Tool (CAIT), Consist of 32 points with a score less than 24 indicating CAI according to the International Ankle Consortium. The tool will be used in the Arabic version. The participants will be asked to choose the most suitable answer, with lower scores indicating greater perceived instability. - Response time. — Assessment will be conducted at baseline and after 4 weeks of intervention
Response time will be measured through the BlazePod™ application, BlazePod™ is a method of motor learning assessment and cognitive motor training. BlazePod™ sensors are reactive lights that turn off or deactivate with contact, They are controlled via smartphone applications using Bluetooth low energy technology and allow for full customization of 10 colored lights which record time variables from activation until deactivation. In this scenario, pods will activate automatically and randomly with a timer and deactivate with the impact of the foot touching the top. Lower response time means better motor learning and is calculated automatically through the BlazePod application. - Self-reported physical function — The questionnaire will be administered at baseline and after 4 weeks of intervention.
Self-reported physical function will be assessed using the Sport subscale of the Foot and Ankle Ability Measure (FAAM), a validated tool for evaluating functional limitations related to sports activities in individuals with foot and ankle disorders. The Sport subscale consists of 8 items, he response to each item on the Sports subscale is scored from 4 to 0, with 4 being "no difficulty" and 0 being "unable to do", scores on each item are added together to get the item score total, the highest potential score of the questioner is 32, The item score total is divided by the highest potential score. This value is multiplied by 100 to get a percentage, A higher score represents a higher level of physical function. with higher scores indicating better function. FAAM sport subscale will be used in Arabic version.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Aman physical therapy center | Alexandria | Egypt |
More Cairo University trials in Egypt
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07078916 on ClinicalTrials.gov ↗ ← All trials in Egypt